In the event of a merger, acquisition, bankruptcy, or sale of assets, your personal information including your genetic data may be transferred to a new owner as part of that transaction. The policy discloses this possibility but the document reviewed does not specify whether users will receive advance notice or a right to object before such a transfer occurs.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This clause operationalizes the user's ability to terminate participation in the service and Research program, while establishing that sample disposal is automated upon deletion. The irreversibility specification creates a procedural checkpoint regarding data and sample retention.
Interpretive note: The full business transaction clause language was not fully reproduced in the document excerpt reviewed; the specific notice obligations and user rights in the event of a transaction may be detailed elsewhere in the full policy.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth is governed by different privacy rules. Previously, the policy stated that users choosing telehealth services coordinated through 23andMe would find healthcare privacy protections described in a separate notice. That reference is now absent from the main privacy statement. Users seeking privacy information specific to telehealth services will need to determine independently whether a separate notice exists or contact 23andMe directly using the provided contact information.
View change record →The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for telehealth services. Users who receive telehealth services coordinated through 23andMe may now lack clear notice of which privacy framework governs their medical records, since the reference to that parallel notice has been removed. The organizational scope change from '23andMe Research Institute' to '23andMe' narrows the explicitly named entities responsible for the policy, though operational impact depends on how these entities actually function.
View change record →A business transaction such as a merger or acquisition could result in your genetic and personal health data being transferred to a new company, potentially one with different privacy policies and data use practices than those you originally agreed to.
How other platforms handle this
We may share your information in connection with, or during negotiations of, any merger, sale of company assets, financing, acquisition, or dissolution, transaction, or proceeding involving all or a portion of our business.
We may disclose certain information, in connection with or during negotiations or closing of any merger, sale of company assets, financing, or acquisition of all or a portion of our business to another company.
We may share your personal information with our affiliates, meaning entities that control, are controlled by, or are under common control with Consensys. We also share information with service providers who assist in operating our services, subject to confidentiality obligations.
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 25 platforms.
"You can delete your 23andMe account any time. If you do, we will automatically opt you out of Research and discard your sample. Keep in mind this process cannot be cancelled or reversed.— Excerpt from 23andMe's 23andMe Privacy Statement
REGULATORY LANDSCAPE: Business transaction data transfers involving genetic data engage GDPR Article 6 lawful basis requirements and, for special category data, Article 9 explicit consent or equivalent grounds; a change of controller in an M&A context may require fresh consent or at minimum advance notification under GDPR. The FTC Act's prohibition on unfair or deceptive practices is relevant if transferred data is used in ways inconsistent with original consent. US state laws including CCPA and state genetic privacy statutes may impose notification requirements on data transfers in M&A contexts. GOVERNANCE EXPOSURE: High. The genetic data held by 23andMe is among the most sensitive categories of personal information, and its transfer to a new corporate owner creates significant governance exposure. The document does not specify whether users will receive advance notice, an opportunity to delete their data before transfer, or a right to object, which may be legally required in certain jurisdictions under GDPR and equivalent frameworks. JURISDICTION FLAGS: EU/EEA users are likely entitled to notification of a change of data controller and may have rights to object or withdraw consent before a transfer. California users have rights under CCPA that may be triggered by a business sale or asset transfer involving personal data. The sensitivity of genetic data may trigger heightened scrutiny from national data protection authorities in Germany, France, and other EU member states known for active genetic data enforcement. CONTRACT AND VENDOR IMPLICATIONS: M&A due diligence teams reviewing a potential acquisition of 23andMe should treat the genetic data asset as a significant liability, requiring assessment of consent validity, data subject rights obligations, and international transfer compliance. Representations and warranties regarding the adequacy of privacy consents and the transferability of genetic data should be carefully negotiated. COMPLIANCE CONSIDERATIONS: Legal teams should evaluate whether the current policy language provides sufficient notice of the possibility of a business transaction data transfer to satisfy GDPR transparency requirements and equivalent US standards. A pre-transaction data mapping exercise and legal basis review would be advisable prior to any M&A event. Users who wish to prevent their data from being transferred in such a scenario should be aware that account deletion prior to a transaction is the primary mechanism available.
Full compliance analysis
Regulatory citations, enforcement risk, and due diligence action items.
Free: track 1 platform + weekly digest. Monitor: 25 platforms + same-day alerts. No credit card required.
ConductAtlas detected a major restructuring of Meta’s privacy policy that removed detailed consumer rights disclosures and relocated them to separate documents.
Your genetic data may be transferred to a new owner as a business asset. Here is what the Terms of Service actually say and what you can do right now.
Compliance Governance Intelligence
Need to monitor specific governance provisions?
Compliance includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
This clause operationalizes the user's ability to terminate participation in the service and Research program, while establishing that sample disposal is automated upon deletion. The irreversibility specification creates a procedural checkpoint regarding data and sample retention.
A business transaction such as a merger or acquisition could result in your genetic and personal health data being transferred to a new company, potentially one with different privacy policies and data use practices than those you originally agreed to.
ConductAtlas has identified this type of provision across 2 platforms. See the full comparison.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.